Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057)

1. Horn, L.
2. Spigel, D.R.
3. Vokes, E.E.
4. Holgado, E.
5. Ready, N.
6. Steins, M.
7. Poddubskaya, E.
8. Borghaei, H.
9. Felip, E.
10. Paz-Ares, L.
11. Pluzanski, A.
12. Reckamp, K.L.
13. Burgio, M.A.
14. Kohlhäeufl, M.
15. Waterhouse, D.
16. Barlesi, F.
17. Antonia, S.
18. Arrieta, O.
19. Fayette, J.
20. Crinò, L.
21. Rizvi, N.
22. Reck, M.
23. Hellmann, M.D.
24. Geese, W.J.
25. Li, A.
26. Blackwood-Chirchir, A.
27. Healey, D.
28. Brahmer, J.
29. Eberhardt, W.E.E.
30. Mostrar todos los/as autores/as +